Comparative Analysis of Neoadjuvant Immunochemotherapy and Neoadjuvant Targeted Therapy Combined with Chemotherapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Retrospective Investigation - Summary - MDSpire
Advertisement
Comparative Analysis of Neoadjuvant Immunochemotherapy and Neoadjuvant Targeted Therapy Combined with Chemotherapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Retrospective Investigation
To compare the effectiveness of neoadjuvant immunochemotherapy (NICT) and neoadjuvant targeted therapy plus chemotherapy (NTCT) specifically in patients with EGFR mutant tumors.
Key Findings:
A total of 89 patients were included in the study, with a median age of 57 years, and specific MPR and pCR rates were observed.
Interpretation:
The findings suggest potential differences in treatment efficacy between NICT and NTCT in EGFR-mutated NSCLC, which may have important clinical implications and warrant further investigation.
Limitations:
Retrospective design may introduce selection bias and affect the reliability of the findings.
Limited sample size may affect generalizability of results.
Data collection relied on existing hospital records, which may have inconsistencies.
Conclusion:
This study provides insights into the comparative effectiveness of NICT versus NTCT in EGFR-mutated NSCLC, highlighting the need for larger prospective studies to confirm findings.
